http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Zhian Jin,Pujie Wang,Jie Chen,Li He,Lijia Xiao,Kaisen Yong,Shenglin Deng,Lin Zhou 연세대학교의과대학 2018 Yonsei medical journal Vol.59 No.5
Purpose: C-end rule (CendR) peptides are found to enhance the penetration of chemotherapeutic agents into tumor cells, whileGX1 is a peptide that homes to gastric cancer (GC) vasculature. This study aimed to synthesize a novel peptide GX1-RPAKPAR(GXC) and to explore the effect of GXC on sensitizing GC cells to chemotherapeutic agents. Materials and Methods: Intracellular Adriamycin concentration analysis was applied to conform whether GXC peptide increasesthe penetration of chemotherapeutic agents into GC cells in vitro. The effect of GXC peptide on sensitizing GC cells to chemotherapeuticswas validated by apoptosis assay and in vitro/vivo drug sensitivity assay. The specificity of GXC to GC tissue was validatedby ex vivo fluorescence imaging. Results: In vitro, administration of GXC significantly increased Adriamycin concentrations inside SGC-7901 cells, and enhancedthe efficacy of chemotherapeutic agents by decreasing the IC50 value. In vivo, FITC-GXC specifically accumulated in GC tissue. Moreover, systemic co-injection with GXC peptide and Adriamycin statistically improved the therapeutic efficacy in SGC-7901xenograft models, surprisingly, without obviously increasing side effects. Conclusion: These results demonstrated that co-administration of the novel peptide GXC with chemotherapeutic agents may bea potential way to enhance the efficacy of anticancer drugs in GC treatment.